ANNOUNCE prompts questions over the Accelerated Approval process

Nature Reviews Clinical Oncology, Published online: 27 June 2019; doi:10.1038/s41571-019-0246-9The negative results of the ANNOUNCE trial, resulting in withdrawal of olaratumab from the market, illustrate the difficulties in balancing access to novel therapies with the need for proven benefit.
Source: Nature Reviews Clinical Oncology - Category: Cancer & Oncology Source Type: research